Pfizer Stock Price, News & Analysis

Pfizer Inc. (NYSE:PFE) announced significant results from the Phase 3 CROWN trial of LORBRENA® (lorlatinib) versus XALKORI® (crizotinib) for previously untreated ALK-positive advanced non-small cell lung cancer (NSCLC). LORBRENA showed a statistically significant improvement in progression-free survival (PFS) with a 72% risk reduction of progression or death (HR 0.28, p<0.001). Furthermore, the objective response rate was 76% for LORBRENA versus 58% for XALKORI. These findings will be reviewed under the FDA's Real-Time Oncology Review pilot program for potential first-line indication.

Pfizer and BioNTech have announced that their mRNA-based COVID-19 vaccine candidate, BNT162b2, has achieved a 95% efficacy rate in their Phase 3 trial, surpassing all primary endpoints. The study involved 43,661 participants, with the data showing efficacy consistent across demographics. The companies are preparing to submit a request for Emergency Use Authorization (EUA) from the FDA, following the achievement of the required safety milestone. They aim to produce up to 50 million doses in 2020 and up to 1.3 billion by the end of 2021.

Pfizer Inc. (NYSE: PFE) has completed the spin-off of its Upjohn Business, merging it with Mylan N.V. to create Viatris Inc. This all-stock Reverse Morris Trust transaction allows Pfizer shareholders to receive approximately 0.124079 shares of Viatris for each Pfizer share held. Post-transaction, Pfizer shareholders own about 57% of Viatris, with Mylan shareholders holding the remaining 43%. Pfizer has not updated its financial guidance, noting that contributions from Upjohn will be treated as discontinued operations.

Pfizer Inc. (NYSE: PFE) announced the publication of an analysis confirming that higher doses of VYNDAQEL (tafamidis meglumine) 80 mg and VYNDAMAX (tafamidis) 61 mg significantly improve long-term survival in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) compared to the lower dose of VYNDAQEL 20 mg. The analysis, detailed in the European Journal of Heart Failure, indicated a 30% reduction in mortality risk, increasing to 43% after adjusting for variables. These findings reinforce the use of VYNDAQEL 80 mg and VYNDAMAX 61 mg as optimal dosing for ATTR-CM patients.

Pfizer Inc. (NYSE: PFE) invites the public to a webcast featuring Angela Hwang, Group President of the Biopharmaceuticals Group, at the 2nd Annual Wolfe Research Healthcare Conference. This event will take place on Wednesday, November 18, 2020, at 9:50 a.m. EST. Investors can access the live discussion and archived copy on Pfizer's investor website, where more information on participation is available. The webcast may include forward-looking statements about Pfizer's financial performance, product pipeline, and responses to COVID-19.

Pfizer Inc. (NYSE: PFE) reported positive top-line results from the Phase 3 JADE REGIMEN study of abrocitinib, a JAK1 inhibitor for moderate to severe atopic dermatitis. The 52-week study showed significant efficacy, with 81.1% of patients on 200mg and 57.4% on 100mg preventing flares, compared to 19.1% on placebo (p<0.0001). The study also demonstrated a higher percentage of patients maintaining an Investigator's Global Assessment (IGA) score of clear or almost clear. Out of 1,233 participants, 798 (64.7%) had positive responses during the induction phase, exceeding expectations.

Pfizer (PFE) and BioNTech have finalized a supply agreement with the European Commission for 200 million doses of their BNT162b2 COVID-19 vaccine, with an option for an additional 100 million doses. Deliveries are expected to commence by the end of 2020, contingent on successful clinical trials and regulatory approval. The vaccine will be manufactured in Germany and Belgium. This supply agreement marks a significant step in making a COVID-19 vaccine accessible in the EU, aiming to protect vulnerable populations amidst the pandemic.

Pfizer (PFE) and BioNTech announced that their mRNA-based vaccine candidate, BNT162b2, has shown efficacy against COVID-19 in a Phase 3 clinical trial. The first interim analysis reported a vaccine efficacy rate above 90% based on 94 cases, achieved 7 days after the second dose. The trial has enrolled 43,538 participants to date, with diverse backgrounds. Pfizer plans to produce up to 50 million doses in 2020 and 1.3 billion doses in 2021. The companies are preparing data for regulatory submission and will continue to collect safety and efficacy data.

Pfizer Inc. (NYSE: PFE) announced positive Phase 3 study results for tofacitinib in adults with active ankylosing spondylitis, demonstrating significant efficacy compared to placebo. The study, which included 270 participants, met both its primary and key secondary endpoints, showing ASAS20 responses of 56.4% versus 29.4% for placebo, and ASAS40 responses of 40.6% compared to 12.5%, respectively. Tofacitinib is not yet FDA-approved for this indication, but a presentation is scheduled for November 9 during ACR Convergence. The company anticipates FDA review with a PDUFA goal date in Q2 2021.